Studies find uneven uptake of biosimilars as availability increases
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesProduct LifecycleReimbursementUnited StatesRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesProduct LifecycleReimbursementUnited States